Effects of Gefitinib on Androgen Levels in Lung Cancer Patients
Author Information
Author(s): Nishio M, Ohyanagi F, Horiike A, Ishikawa Y, Satoh Y, Okumura S, Nakagawa K, Nishio K, Horai T
Primary Institution: Cancer Institute Hospital, Japanese Foundation For Cancer Research
Hypothesis
Androgens may play an important role in the efficacy of gefitinib in NSCLC cases.
Conclusion
Gefitinib treatment significantly lowers androgen levels in non-small-cell lung cancer patients, particularly in women without a smoking history.
Supporting Evidence
- Gefitinib treatment significantly suppressed androgen levels in both men and women.
- Women who responded to gefitinib had lower hormone levels during treatment compared to nonresponders.
- Testosterone and DHEA levels were significantly lower during treatment than pretreatment in both genders.
Takeaway
This study found that a cancer treatment called gefitinib lowers certain hormones in patients, especially in women who don't smoke, which might help the treatment work better.
Methodology
Patients were treated with gefitinib monotherapy, and serum androgen levels were measured before and during treatment.
Potential Biases
Potential bias due to the small sample size and retrospective nature of the study.
Limitations
The study is small and retrospective, and further large-scale prospective trials are needed.
Participant Demographics
67 patients (36 men and 31 women), median age 61 years, with 38.8% having never smoked.
Statistical Information
P-Value
p<0.0001 for testosterone levels between men and women
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website